Institutional shares held 158 Million
1.88M calls
688K puts
Total value of holdings $2.35B
$28M calls
$10.3M puts
Market Cap $2.41B
161,843,008 Shares Out.
Institutional ownership 97.43%
# of Institutions 299


Latest Institutional Activity in ACAD

Top Purchases

Q1 2024
Rtw Investments, LP Shares Held: 13.8M ($206M)
Q1 2024
Squarepoint Ops LLC Shares Held: 1.01M ($15M)
Q1 2024
Canada Pension Plan Investment Board Shares Held: 662K ($9.86M)
Q1 2024
Prudential Financial Inc Shares Held: 1.07M ($16M)
Q1 2024
Avidity Partners Management LP Shares Held: 589K ($8.77M)

Top Sells

Q1 2024
Price T Rowe Associates Inc Shares Held: 4M ($59.6M)
Q1 2024
D. E. Shaw & Co., Inc. Shares Held: 2.64M ($39.4M)
Q1 2024
Fred Alger Management, LLC Shares Held: 2.26M ($33.7M)
Q1 2024
Fuller & Thaler Asset Management, Inc. Shares Held: 73 ($1.09K)
Q1 2024
Alyeska Investment Group, L.P. Shares Held: 85.7K ($1.28M)

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Insider Transactions at ACAD

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
534K Shares
From 15 Insiders
Grant, award, or other acquisition 92.8K shares
Exercise of conversion of derivative security 441K shares
Sell / Disposition
366K Shares
From 6 Insiders
Open market or private sale 363K shares
Bona fide gift 2.92K shares

Track Institutional and Insider Activities on ACAD

Follow ACADIA PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD